Onco Actu du 8 septembre 2016

	4. Dépistage, diagnostic et pronostic
Infra-red light to detect early signs of oesophageal cancer [Cancer Research UK] This new technique could be used to monitor people with Barrett’s oesophagus who have an increased risk of developing oesophageal cancer, and spot early signs that cancer might be developing before the person has any symptoms.
	4.11 Dép., diag. & prono. - Ovaire
FDA warns against widely used ovarian cancer screening test [STAT] The FDA’s announcement was praised by the Ovarian Cancer Research Fund Alliance, which has advocated such a move.
The FDA recommends against using screening tests for ovarian cancer screening: FDA Safety Communication [FDA] Based on currently available information, the FDA recommends against using currently offered tests to screen for ovarian cancer.
	4.13 Dép., diag. & prono. - Peau
Nanotechnology Supports Treatment of Malignant Melanoma [University of Basel] In this study, the Basel research team was able to demonstrate that nanomechanical microcantilevers can identify mutations in complex mixtures of total RNA isolated from tissue samples.
	4.5 Dép., diag. & prono. - Colorectal
Single-letter variation in DNA linked to longer bowel cancer survival [The Institute of Cancer Research] Researchers at the ICR and The Royal Marsden analysed tumour samples from 155 patients treated for advanced rectal cancer for SNPs in miR-608, to see if some patients might benefit from additional treatments.
	5. Traitements
Approach May Allow for Stem Cell Transplant without Radiation, Chemotherapy [NCI] In a proof-of-concept study in mice, researchers from the Stanford University School of Medicine successfully performed hematopoietic (blood) stem cell (HSC) transplants (also called bone marrow transplants) without first using radiation or chemotherapy.
	5.12 Immunothérapies
With Opdivo in its sights, Merck's Keytruda nabs breakthrough tag in first-line lung cancer [FiercePharma] It’s a big turnabout for Opdivo, which had been expected to dominate the checkpoint inhibitor field.
FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer [Merck] Merck Has Also Submitted a Marketing Authorization Application to the European Medicines Agency for KEYTRUDA in the Same Patient Population.
Immunotherapy Clinical Tests Spur Hope, and Plenty of Headaches [Xconomy] Dropouts are not a new problem for clinical trials. But the problem could be starker with some immunotherapies because the gap between their performance and that of the old standard of care is extraordinary for some patients, and others don’t want to be denied the chance at a similar result.
	5.12.1 Immunothérapies - partenariats
Genentech, BioLineRx pair up a checkpoint inhibitor combo [FierceBiotech] The partners will test BL-8040, BioLineRx's lead oncology candidate that is a CXCR4 antagonist, in combination with Genentech’s atezolizumab in multiple cancer indications in Phase 1b testing designed to assess the safety and tolerability of the combo, as well as its pharmacodynamic parameters in hematologic malignancies and solid tumors.
	5.12.2 Immunothérapies - CAR-T
Clinical Data Published in Science Translational Medicine: Patients with Advanced Lymphoma in Remission after T-cell Therapy [Juno] The paper reported the results of the first 32 patients in a dose-finding trial of JCAR014 following a round of chemotherapy, called lymphodepletion, designed to create a more favorable environment for the CAR T cells to grow in the patient’s body.
	5.2.1 Pharma - Partenariats
Agios Blood Cancer Drug Heading to Early FDA Filing by Partner Celgene [The Street] Celgene owns the rights to the Agios drug known as AG-221 under an existing partnership.
	5.3 Traitements - FDA, EMA,...
Workshop on adaptive pathways - discussing a concept for development of medicines addressing unmet medical needs [EMA] Registration is now open.
FDA slams drug maker for touting unapproved leukemia treatment to docs [STAT] Earlier in the year, Celator reported positive clinical trial results for the drug, which combines two currently available medications in a new formulation. But that’s not the same thing as having clearance to market a product. Unfortunately, that’s the impression regulators had after looking at the poster.
	5.4 Traitements - Economie
Fixing Drug Pricing Means Paying For “Value” [The Incidental Economist] But “value,” in the health care system, is somewhat abstract. What value? To whom? And how its measured? are all controversial, unsettled questions.
	6. Lutte contre les cancers
Improving care for cancer patients in Northern Ireland [Cancer Research UK] The chances of developing cancer in Northern Ireland are slightly lower than in other parts of the UK, but the number of people dying from cancer as a proportion of the population is higher than the UK average.
	6.10.1 Politiques (USA)
AACR Embraces Cancer Moonshot Blue Ribbon Panel’s Recommendations [AACR] The American Association for Cancer Research urges Congress to provide funding support for these breakthrough research opportunities.
ASCO Applauds Bold Recommendations from Cancer Moonshot Blue Ribbon Panel [ASCO] ASCO's recommendations included enhanced access to clinical outcomes databases, like the Society's CancerLinQ™, to help learn from all cancer patients and a sustained, well-funded national cancer research system and clinical cancer research infrastructure. ASCO is pleased that these recommendations were incorporated into the final report.
Top scientists lay out sweeping recommendations for ‘moonshot’ against cancer [STAT] There is at least one caveat, however: As the panel itself notes, there is currently limited evidence about whether tumor profiling actually leads to better care, though that is attributed at least in part to the limited ability of researchers to collect the large amounts of data needed to prove its effectiveness.
Cancer Moonshot Panel Details Necessary Steps to Accelerate Cancer Research and Prevention [ACS] “To truly maximize our potential to accelerate progress we must support new scientific investigation while simultaneously making the benefits of completed prevention and treatment research available to the entire population.”
Blue ribbon report urges U.S. cancer moonshot to invest in 10 promising areas [Science] The panel’s 10 recommendations, from studies of tumor biology to research on patient care (see table, below), don’t contain any big surprises.
Cancer experts unveil wishlist for US government ‘moonshot’ [Nature] “They did a pretty good job,” he says. “I was glad they didn’t just say, ‘Oh we just need to sequence more tumours.’”
Blue Ribbon Panel 2016 [NCI] The report describes 10 transformative research recommendations for achieving the Cancer Moonshot's ambitious goal of making a decade's worth of progress in cancer prevention, diagnosis, and treatment in just 5 years.
NCI’s Moonshot Advisory Panel Identifies Ten Opportunities in Cancer Research [The Cancer Letter] The panel considered over 1,600 ideas and initially proposed 13 recommendations, which were narrowed to 10 in the report.
'Moonshot' cancer panel calls for US to create national research database [The Guardian] Top US cancer scientists have urged the Obama administration to create a national cancer database for clinicians and patients as part of a slew of recommendations presented on Wednesday by the White House-supported cancer “moonshot” panel.